|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||6.42 - 6.92|
|52-week range||4.31 - 16.05|
|PE ratio (TTM)||N/A|
|Earnings date||7 May 2018 - 11 May 2018|
|Forward dividend & yield||N/A (N/A)|
|1y target est||8.57|
President Donald Trump said he's considering suing drugmakers for their role in fueling the opioid epidemic, sending pharma stocks tumbling.
NEWARK, Calif., March 19, 2018-- Depomed, Inc. today announced it has signed a lease for its new corporate headquarters at 100 South Saunders Road in Lake Forest, Illinois, a northern Chicago suburb. The ...
NEW YORK, March 09, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
Collegium touched a buy zone Thursday after sales of painkiller Xtampza easily beat Street expectations in the fourth quarter.
In fiscal 2017, Depomed (DEPO) generated total revenues of $380.7 million. Of these total revenues, $379.8 million came from product sales, and ~$844,000 came from royalties. By comparison, the company had generated total revenues of $455.8 million in fiscal 2016, of which $455 million came from product sales and $831 million from royalties.
Depomed (DEPO) has adopted a three-pronged business strategy with three key elements: maintain, build, and grow. Depomed aims to maintain its Nucynta franchise of pain products through the commercialization agreement it entered into with Collegium Pharmaceutical in December 2017. Under this agreement, Depomed granted commercialization rights for the Nucynta franchise of pain products to Collegium Pharmaceutical in the US.
Depomed (DEPO) generates a major part of its sales from five major products: Nucynta, Gralise, Cambia, Lazanda, and Zipsor. Sales of products in Depomed’s Nucynta franchise fell from $281.2 million in fiscal 2016 to $239.5 million in fiscal 2017. Depomed acquired the Nucynta franchise from Janssen in April 2015.
Depomed (DEPO) is a specialty pharmaceutical company with a focus on pain and CNS (central nervous system) conditions. In March 2018, two of the seven analysts covering Depomed have given the stock a “buy” rating. By comparison, of the 22 analysts covering Merck (MRK) in March 2018, six analysts have given the stock a “strong buy” rating, and seven analysts have given it a “buy” rating, while nine analysts have given it a “hold” rating.
NEWARK, Calif., March 06, 2018-- Depomed, Inc. today announced that members of senior management will participate in fireside chats at the following healthcare conferences during the month of March.. 30th ...
On a per-share basis, the Newark, California-based company said it had a loss of 52 cents. Earnings, adjusted for non-recurring costs and pretax expenses, were 15 cents per share. The results beat Wall ...
-Annual Net Revenues of $381 Million-. -Collegium, Slán Transactions and Expanded Neurology Field Force Position Company for Improved Profitability in 2018 and Beyond–. -New Corporate Headquarters Expected ...
NEWARK, Calif., Feb. 20, 2018-- Depomed, Inc. today announced that it will release fourth quarter fiscal year 2017 financial results on Tuesday, February 27, 2018, after the close of markets. The Company ...
NEWARK, Calif., Feb. 07, 2018--. Depomed, Inc. today announced that members of senior management will participate in fireside chats at the following healthcare conferences during the month of February.. ...
NEWARK, Calif., Jan. 10, 2018-- Depomed, Inc. today announced the closing of its previously disclosed Commercialization Agreement for the U.S. rights to commercialize both NUCYNTA ® Extended Release and ...
Collegium rocketed to a 22-month high Tuesday after striking a deal with Depomed to commercialize its painkiller Nucynta.